FOXN1 and cancer: Furthermore, tumor-specific survival data were accessible for a cohort of 80 patients, and our analysis revealed a meaningful correlation between the expression of FOXN1 and the cancer-specific survival rates in LUSC patients (Fig. 4, 38 vs 42 patients; median survival 52 months vs 25 months; P = 0.039).